European stocks closed broadly lower
According to Golden Ten data, the German DAX30 index closed down 60.23 points, or 0.33%, on April 24 (Wednesday), at 18082.35 points;
The UK's FTSE 100 Index closed down 5.36 points, or 0.07%, on Wednesday, April 24, at 8039.45 points;
France's CAC40 index closed down 13.92 points, or 0.17%, on Wednesday, April 24, at 8091.86 points;
The European Stoxx 50 Index closed down 19.32 points, or 0.39%, on Wednesday, April 24, at 4988.85 points;
Spain's IBEX35 index closed down 46.90 points, or 0.42%, on Wednesday, April 24, at 11028.50 points;
Italy's FTSE MIB index closed down 98.75 points, or 0.29%, on Wednesday, April 24, at 34265.00 points.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$40 billion in bond issuance with a maximum interest rate of 8.3%! SpaceX (SPCX.US) AI gamble also exposes the “funding winter” for AI infrastructure
According to media reports citing sources familiar with the matter, SpaceX is preparing to complete a debt issuance totaling $40 billion, with an interest rate significantly higher than previous borrowing costs, reflecting growing investor concerns over financing for artificial intelligence (AI) infrastructure.
Tom Lee: The market is in a sell-off state, and tech stocks have reached support levels
TS Lombard scenario analysis: An AI bubble burst could trigger a 30% plunge in the S&P 500, wiping out 20 trillion dollars in market value—but don't rush to short!
Dario Perkins from TS Lombard predicted in a scenario analysis released on Thursday that if AI capital expenditure collapses, approximately $20 trillions in U.S. stock market value could evaporate, triggering credit losses of $125 billions to $190 billions.
Gilead Sciences (GILD.US) acquires PepStar’s oral inflammation drug program for $1.275 billion in cash, increasing investment in inflammatory bowel disease pipeline
Gilead Sciences will acquire PepStar’s anti-inflammatory drug program for $1.28 billions.
Crypto prices
More
